Deciphera Pharmaceuticals to be Acquired by Ono Pharmaceutical for $2.4 Billion
Deciphera Pharmaceuticals announced on April 29 that it has entered into a definitive merger agreement with Ono Pharmaceutical Co., Ltd. Ono will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of Ono, for a total equity value of $2.4 billion. Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the... Read More »
Vertex Pharmaceuticals Purchases Alpine Immune Sciences $4.9 Billion
Vertex Pharmaceuticals announced that it has agreed to acquire Seattle-based Alpine Immune Sciences for $4.9 billion. Alpine Immune Sciences is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. According to its most recent annual report, the company’s revenue for FY 2023 was approximately $58.9 million, and EBITDA was -$43.3 million. Vertex Pharmaceuticals is an American biopharmaceutical company based in... Read More »
Highbridge Capital Management Acquires Gamida Cell for $70 Million
Highbridge Capital Management, based in New York City, announced on March 27 that it entered into an agreement to acquire Gamida Cell, an Israeli biotechnology company. The agreement will see Highbridge Capital Management convert $75 million of existing unsecured convertible senior notes into equity in Gamida as well as supply $30 million of new capital to Gamida. Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. Its proprietary nicotinamide technology expands the number of cells while maintaining their intrinsic properties to create potentially curative cell therapy products and candidates for patients with cancer. Gamida entered 2024... Read More »
Novo Nordisk Inks $1 Billion Buyout of Cardior Pharmaceuticals
Novo Nordisk announced that it has agreed to acquire Cardior Pharmaceuticals for up to €1.025 billion (approximately $1.1 billion USD), including an upfront payment and additional payments if certain development and commercial milestones are achieved. The acquisition is an important step forward in Novo Nordisk’s strategy to establish a presence in the cardiovascular disease treatment space. Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse cardiovascular diseases. Cardior’s therapeutic approach uses distinctive non-coding RNAs as a platform for addressing... Read More »AbbVie Acquires Landos Biopharma for $137.5 Million
On March 25, Chicago-based AbbVie Inc. announced that it entered into an agreement to acquire Landos Biopharma for $137.5 million. AbbVie will acquire Landos at a price of $20.42 per share in cash upon closing, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million in the aggregate, subject to the achievement of a clinical development milestone. Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class oral NLRX1... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
